牛俊奇 贾继东：乙型肝炎创新药物临床试验设计的临床考量

hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3):

230-238. DOI: 10.2471/BLT.18.219469.

[2] Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and

endpoints of clinical trials in chronic hepatitis B -report from the 2019

EASL-AASLD HBV treatment endpoints conference[J]. J Hepatol,

2020, 72(3): 539-557. DOI: 10.1016/j.jhep.2019.11.003.

[3] 国家食品药品监督管理总局 . 慢性乙型肝炎抗病毒治疗药物临

床试验技术指导原则 [J]. 中国病毒病杂志 , 2018, 8(4): 241-247.

State Food and Drug Administration. Technical guidelines for clinical

trials of antiviral drugs for chronic hepatitis B[J]. Chin J Viral Dis,

2018, 8(4): 241-247.

[4] Food and Drug Administration. Chronic hepatitis B virus infection:

developing drugs for treatment; draft guidance for industry;

availability[EB/OL]. https: //www.federalregister.gov/.

[5] Hui CK, Leung N, Yuen ST, et al. Natural history and disease

progression in Chinese chronic hepatitis B patients in immune-tolerant

phase[J]. Hepatology, 2007, 46(2): 395-401. DOI: 10.1002/hep.21724.

[6] Sibille M, Patat A, Caplain H, et al. A safety grading scale to support

dose escalation and define stopping rules for healthy subject first-

entry-into-man studies: some points to consider from the French Club

Phase I working group[J]. Br J Clin Pharmacol, 2010, 70(5): 736-748.

DOI: 10.1111/j.1365-2125.2010.03741.x.

[7] Jarow JP, Casak S, Chuk M, et al. The majority of expedited

investigational new drug safety reports are uninformative[J]. Clin

Cancer Res, 2016, 22(9): 2111-2113. DOI: 10.1158/1078-0432.CCR-

15-2082.

[8] Sacks LV, Shamsuddin HH, Yasinskaya YI, et al. Scientific and

regulatory reasons for delay and denial of FDA approval of initial

applications for new drugs, 2000-2012[J]. JAMA, 2014, 311(4): 378-

384. DOI: 10.1001/jama.2013.282542.

[9] Lorch U, Berelowitz K, Ozen C, et al. The practical application of

adaptive study design in early phase clinical trials: a retrospective

analysis of time savings[J]. Eur J Clin Pharmacol, 2012, 68(5): 543-

551. DOI: 10.1007/s00228-011-1176-3.

[10] Narjes H, Nehmiz G. Effect of hospitalisation on liver enzymes in

healthy subjects[J]. Eur J Clin Pharmacol, 2000, 56(4): 329-333. DOI:

10.1007/s002280000142.

[11] Cai Z, Christianson AM, Ståhle L, et al. Reexamining transaminase

elevation in Phase I clinical trials: the importance of baseline and

change from baseline[J]. Eur J Clin Pharmacol, 2009, 65(10): 1025-

1035. DOI: 10.1007/s00228-009-0684-x.

[12] Zhou J, Song L, Zhao H, et al. Serum hepatitis B core antibody as a

biomarker of hepatic inflammation in chronic hepatitis B patients with

normal alanine aminotransferase[J]. Sci Rep, 2017, 7(1): 2747. DOI:

10.1038/s41598-017-03102-3.

[13] Rajoriya N, Combet C, Zoulim F, et al. How viral genetic variants

and genotypes influence disease and treatment outcome of chronic

hepatitis B. Time for an individualised approach?[J]. J Hepatol, 2017,

67(6): 1281-1297. DOI: 10.1016/j.jhep.2017.07.011.

[14] Liaw YF. Natural history of chronic hepatitis B virus infection and

long-term outcome under treatment[J]. Liver Int, 2009, 29 Suppl 1:

100-107. DOI: 10.1111/j.1478-3231.2008.01941.x.

[15] Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis

B virus infection: towards a cure[J]. Nat Rev Drug Discov, 2019,

18(11): 827-844. DOI: 10.1038/s41573-019-0037-0.